Rakovina Therapeutics Inc.
RKV.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 83.72% | 135.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.57% | 43.47% | |||
| Operating Income | -47.57% | -43.47% | |||
| Income Before Tax | -43.28% | -42.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.28% | -42.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.28% | -42.35% | |||
| EBIT | -47.57% | -43.47% | |||
| EBITDA | -53.16% | -51.14% | |||
| EPS Basic | -1.89% | -27.71% | |||
| Normalized Basic EPS | -3.08% | -25.00% | |||
| EPS Diluted | -6.92% | -56.63% | |||
| Normalized Diluted EPS | -3.08% | -25.00% | |||
| Average Basic Shares Outstanding | 40.47% | 11.77% | |||
| Average Diluted Shares Outstanding | 40.47% | 11.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||